GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » 14-Day RSI

Protagenic Therapeutics (Protagenic Therapeutics) 14-Day RSI : 47.37 (As of Apr. 27, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-27), Protagenic Therapeutics's 14-Day RSI is 47.37.

The industry rank for Protagenic Therapeutics's 14-Day RSI or its related term are showing as below:

PTIX's 14-Day RSI is ranked worse than
60.44% of 1575 companies
in the Biotechnology industry
Industry Median: 44.62 vs PTIX: 47.37

Competitive Comparison of Protagenic Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Protagenic Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's 14-Day RSI falls into.



Protagenic Therapeutics  (NAS:PTIX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protagenic Therapeutics  (NAS:PTIX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Protagenic Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367

Protagenic Therapeutics (Protagenic Therapeutics) Headlines

From GuruFocus

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 03-22-2023